Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

The Japan-specific dosage of rivaroxaban was found to be non-inferior to warfarin with respect to the incidence of major and non-major clinically relevant bleeding, and was associated with a lower incidence of intracranial bleeding and a strong trend for a lower incidence of stroke/SE compared with warfarin [ 9 ].

also in 5,725 other papers